2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
There was some steady progress in neurology – in February FDA approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class. The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout. months, compared with 6.7
96 
Let's personalize your content